Durgical
EN
Open the app

Amyloidosis: AL, ATTR and AA

  • Look-alikes compared

Amyloid is misfolded protein that stiffens the heart and clogs the kidneys. Which protein it is decides the treatment, so typing is never optional.

Updated

What it is

Amyloidosis is the deposit in tissues of a protein that has misfolded into rigid fibrils. The fibrils look the same under the microscope whatever their origin, and stain with Congo red to show apple-green birefringence in polarised light. The main systemic types are AL (immunoglobulin light chains from a plasma cell clone), ATTR (transthyretin, either wild-type in older people or hereditary from a TTR variant) and AA (serum amyloid A, from long-lasting inflammation).

The difference in one line

  • AL: a plasma cell clone, often small, makes toxic light chains (lambda more often than kappa); heart, kidney (nephrotic syndrome), liver, nerves, gut; big tongue and bruising around the eyes are specific clues.
  • AL is a medical emergency in slow motion: untreated cardiac AL can kill within months, so diagnosis should be fast.
  • Wild-type ATTR: mainly older men with heart failure and thick heart walls; carpal tunnel syndrome in both wrists and lumbar canal stenosis often precede it by years.
  • Hereditary ATTR: autosomal dominant TTR variants; some cause mainly neuropathy with autonomic failure (Val30Met), others mainly cardiomyopathy (Val122Ile, carried by a notable minority of people of West African ancestry).
  • AA: chronic inflammation (rheumatoid arthritis, inflammatory bowel disease, familial Mediterranean fever, tuberculosis, bronchiectasis, chronic osteomyelitis); usually presents with proteinuria and kidney failure.
  • Clues to cardiac amyloid: thick ventricular walls with low-voltage ECG, heart failure with preserved ejection fraction, a high NT-proBNP and troponin, intolerance of usual heart failure drugs.

Three amyloidoses side by side

FeatureALATTR (wild-type or hereditary)AA
PrecursorImmunoglobulin light chainTransthyretin made by the liverSerum amyloid A (acute-phase protein)
WhoAdults, often with a small paraproteinOlder men (wild-type); families with a TTR variantLong-standing inflammatory or infectious disease
Main organsHeart, kidney, liver, nerves, soft tissueHeart; nerves in some hereditary formsKidney, then liver, spleen, gut
Distinctive clueBig tongue, periorbital bruising, nephrotic syndromeBilateral carpal tunnel, spinal stenosis, biceps tendon ruptureProteinuria in a patient with chronic inflammation
How confirmedBiopsy with typing; monoclonal light chainsBone scintigraphy uptake with no monoclonal protein; TTR gene testBiopsy with typing; raised SAA and CRP
Treat the sourceChemotherapy against the plasma cell cloneTTR stabilisers or TTR silencersControl the inflammation (for example colchicine in FMF)

In clinical practice

  • A patient with nephrotic syndrome, heart failure with thick walls and a peripheral neuropathy should be tested for AL amyloidosis the same week.
  • An older man with heart failure who had carpal tunnel surgery on both hands years ago fits wild-type ATTR.
  • MGUS is common in older people: a small paraprotein in a patient with cardiac amyloid does not prove AL, and the deposit must be typed.
  • Heart failure drugs that lower blood pressure or heart rate are often poorly tolerated in cardiac amyloid; diuretics remain the mainstay of symptom control.

How it is confirmed

  • Every suspected case: serum and urine immunofixation and serum free light chains, to look for AL first.
  • Suspected cardiac amyloid without a monoclonal protein: bone scintigraphy with a technetium-labelled bone tracer; strong cardiac uptake with no monoclonal protein confirms ATTR without a biopsy.
  • Any monoclonal protein, or kidney or nerve disease: tissue biopsy (fat pad, marrow or the affected organ) with Congo red and typing by mass spectrometry or immunostaining.
  • Confirmed ATTR: TTR gene testing to separate wild-type from hereditary, and genetic counselling for relatives.
  • Staging and follow-up: NT-proBNP, troponin, echocardiogram or cardiac MRI, and urine protein.

Common traps

  • Diagnosing ATTR from a positive bone scan without excluding a monoclonal protein: AL can also take up the tracer.
  • Assuming AL because a paraprotein is present: older patients with ATTR often have an unrelated MGUS.
  • Calling it amyloidosis without typing the fibril: AL and ATTR need completely different treatment.
  • Missing AA in long-standing rheumatoid arthritis or bronchiectasis: a patient with either who develops proteinuria may have it.
  • Delaying AL work-up in a patient with heart involvement: survival can be measured in months.

Test yourself

Think of the answer, then tap the question to see it.

Why must the type of amyloid be identified before treatment begins?

The fibrils look identical, but AL needs therapy against the plasma cell clone, ATTR needs transthyretin stabilisers or silencers, and AA needs control of the inflammation.

An 80-year-old man with heart failure has strong cardiac uptake on bone scintigraphy and a small IgG paraprotein. Is ATTR confirmed?

No; with a monoclonal protein present AL cannot be excluded by the scan, so a tissue biopsy with fibril typing is needed.

Which history in an older man with heart failure and thick ventricular walls points to wild-type ATTR?

Bilateral carpal tunnel syndrome, often years earlier, and lumbar spinal stenosis or biceps tendon rupture.

A patient with decades of bronchiectasis develops heavy proteinuria. Which amyloid is most likely, and what treats it?

AA amyloidosis from chronic inflammation; treatment aims to control the underlying inflammation or infection.

Add to my cards (4)

Elsewhere in DurgiPedia

Connections

← All of haematology

Educational content; it does not replace assessment by a doctor or your institution's protocols. It contains no doses.

Sources: Amyloidosis (StatPearls (NCBI Bookshelf), 2026); Cardiac Amyloidosis (StatPearls (NCBI Bookshelf), 2025); Primary amyloidosis: MedlinePlus Medical Encyclopedia (MedlinePlus, US National Library of Medicine, 2026); Transthyretin amyloidosis: MedlinePlus Genetics (MedlinePlus, US National Library of Medicine, 2026).

Spotted a mistake?We are always improving for the community. Tell us what is wrong and our team will review it.Report a mistake

Representative model, for educational purposes only.